Neurocrine registers Phase 2 trial of NBIP-01435 in classic congenital adrenal hyperplasia

Neurocrine Biosciences had one new registry entry this week, a Phase 2 study of its investigational drug NBIP-01435 in adults with classic congenital adrenal hyperplasia.

• NBIP-01435 is an injectable drug being tested in a Phase 2, open-label study for adults with classic congenital adrenal hyperplasia caused by 21-hydroxylase deficiency, sponsored by Neurocrine Biosciences. The trial is not yet recruiting, with an estimated start date of December 1, 2026¹, and plans to enroll 36 participants¹. The study will track change from baseline in androstenedione (A4) level at Week 8¹ as its primary outcome, with an estimated primary completion date of March 16, 2028.